Paul Rubinstein retweeted
SPANISH BROADCAST CALL OF ARGENTINA'S WINNING GOAL IS ELECTRIC 🔥
(Via @TelemundoSports)
Paul Rubinstein retweeted
Breaking news from #CROI2025: Two probable HIV cures, the Chicago and Oslo Patients, were announced. If confirmed, the total number of known cures will rise to 10. Read article: amfar.org/news/researchers-a…
Paul Rubinstein retweeted
At #CROI2025, our physician researcher @PaulRubinstein4 of @thisisuic @UIHealth presented findings from Chicago Patient (8th person living w/ HIV in remission off #ART after CCR5d32/d32 allogeneic stem cell transplant). @NIAIDNews,#NIAIDVRC,@theNCI & @CookCtyHealth collab vital.
If the men remain in remission, they will be the ninth and tenth known cases of a functional cure after the procedure.
#HIV #HIVCure
poz.com/article/two-people-m…
Paul Rubinstein retweeted
Congrats to our all ⭐️ graduating fellows!!
Dr. Kevin Prescott
Dr. Ana Maria Avila
Dr. Lucas Maahs
We are so excited for what the future holds for you all!
@UICancerCenter – at Chicago, IL
Paul Rubinstein retweeted
CONGRESS | #ASH23 | Franck Morschhauser, University of Lille, presents a post-hoc analysis of the POLARIX study on the prevalence & clinical outcomes of molecularly defined subtypes of DLBCL. N=594, high-risk DHL/THL patients with DZsigPos DLBCL may benefit from Pola-R-CHP vs R-CHOP. According to LymphGen classification, EZB, MCD, and unidentified subtypes may benefit from Pola-R-CHP. #lymphoma #lymsm #leusm
Paul Rubinstein retweeted
Some of our 3rd year fellows Dr. Maahs & Dr. Avila presenting their research @ASH_hematology #ASH23 🩸 @UICancerCenter – at San Diego, CA
Paul Rubinstein retweeted
#ASH23 Thank you to my amazing mentors @Matt_Cortese @Francis77605164 @PaulRubinstein4 and colleagues for visiting my poster and show support! @RoswellHemOnc #lymsm
Paul Rubinstein retweeted
A prospective approach linking individual level pt reported SDOH data to early adverse AML outcomes. Proud of @EshanaShahMD for an excellent oral abstract and the dedicated efforts of leukemia teams, trainees and patients @UICancerCenter and @LurieCancer
Paul Rubinstein retweeted
New! Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
acsjournals.onlinelibrary.wi…
@oncoalert @jasonlukemd @AMC_Studies
Paul Rubinstein retweeted
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study - Rajdev - Cancer - Wiley Online Library acsjournals.onlinelibrary.wi…
Paul Rubinstein retweeted
I'm excited to share that our new paper is published. Many thanks to our wonderful team that made this possible. We are also grateful to the clinical trial participants for their contributions. #kshv #hhv8 #RNAseq #herpes #virus #OpenAccess doi.org/10.1186/s12967-023-0…
Paul Rubinstein retweeted
How I Treat Post-Transplant Lymphoproliferative Disorder ashpublications.org/blood/ar… @jenamengual @columbiacancer @nyphospital
Paul Rubinstein retweeted
Out today in collaboration with @asco, Dr. Reizine & I discuss why exercise is important for patients with prostate cancer, common challenges & types of exercises that may be helpful! 🏃♂️🚴🏽 🧘♂️ 🏋🏽♀️ #prostatecancer #guonc
cancer.net/blog/2023-08/what…
Paul Rubinstein retweeted
Excited to see the important results of BV-AVD in HIV+ Hodgkin lymphoma in print!
2-yr PFS 87% and OS 92% plus increases CD4/CD8 counts. Great work by Paul Rubinstein and @AMC_Studies
sciencedirect.com/science/ar…







































